A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)
Not yet recruitingCTIS2025-525016-41-00
AstraZeneca ABIdiopathic Pulmonary Fibrosis
Target: 28Updated: 2026-08-04